Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib.

MLA

Liling HUANG, et al. “Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-Line Combination Treatment of Pembrolizumab and Anlotinib. (English).” Chinese Journal of Lung Cancer, vol. 24, no. 10, Oct. 2021, pp. 739–42. EBSCOhost, https://doi.org/10.3779/j.issn.1009-3419.2021.102.25.

APA

Liling HUANG, Yan QIN, Fengyi ZHAO, Shengyu ZHOU, & Yuankai SHI. (2021). Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib. (English). Chinese Journal of Lung Cancer, 24(10), 739–742. https://doi.org/10.3779/j.issn.1009-3419.2021.102.25

Chicago

Liling HUANG, Yan QIN, Fengyi ZHAO, Shengyu ZHOU, and Yuankai SHI. 2021. “Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-Line Combination Treatment of Pembrolizumab and Anlotinib. (English).” Chinese Journal of Lung Cancer 24 (10): 739–42. doi:10.3779/j.issn.1009-3419.2021.102.25.